This article from 25/4/23 talks to Neurofilament Light Chain as a surrogate endpoint in Neurology trials being accepted by FDA.
It is a press release from Quanterin Corp, the owners of SIMOA assay.
I'm not sure if it has been posted before, I know there has been discussion on Tofersen, but this article really highlights the critical nature of this biomarker.
The first 2 results were just the warm up act ... the main show is just about to begin.
https://www.businesswire.com/news/home/20230425005796/en/FDA-Accelerated-Approval-of-Tofersen-Highlights-Importance-of-Blood-Neurofilament-Light-Chain-as-Surrogate-Endpoint-in-Neurology-Therapeutic-Trials
Ann: MND Biomarkers and Pharmacodynamics Results, page-333
-
- There are more pages in this discussion • 64 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
0.005(2.86%) |
Mkt cap ! $87.55M | |||
| Open | High | Low | Value | Volume |
| 18.0¢ | 18.0¢ | 17.5¢ | $36.85K | 205.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 162181 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 412357 | 6 |
View Market Depth
| Last trade - 16.10pm 12/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |